GLP‑1 and fertility: timing medications for safer pregnancy planning

Planning pregnancy while taking GLP‑1 receptor agonists requires careful timing of medication changes, monitoring of key biomarkers, and coordination with your clinician. GLP‑1s (glucagon‑like peptide‑1 receptor agonists) can improve weight and glycemic control, which may increase fertility for some people, but they are not recommended during pregnancy. Thoughtful preconception planning helps protect fetal safety while preserving metabolic gains.

Why medication timing matters when planning pregnancy

GLP‑1s are typically stopped before conception because animal studies and limited human data raise concerns about fetal safety. Stopping a medication without a plan can lead to rapid weight regain or loss of glycemic control, both of which can affect fertility and pregnancy outcomes.

Timing matters for three main reasons:

• To allow the drug to clear the body to reduce potential fetal exposure.

• To preserve metabolic control (weight and blood sugar) through other strategies while off the GLP‑1.

• To coordinate fertility care (timing of ovulation induction, assisted reproduction, or natural conception) with a clinician’s plan.

GLP‑1s and pregnancy safety

GLP‑1 receptor agonists — including semaglutide (Wegovy, Ozempic), liraglutide (Saxenda, Victoza), and others — are generally not recommended in pregnancy. Regulatory authorities and product labels advise avoiding pregnancy during treatment and discontinuing when pregnancy is confirmed.

Key safety points:

• Animal reproductive studies have shown potential fetal harm with some GLP‑1 agents; human data are limited.

• If pregnancy occurs, stop the GLP‑1 and consult your clinician promptly to discuss risks and alternative management.

• Use reliable contraception while on GLP‑1s if you are not planning pregnancy.

How GLP‑1 treatment interacts with fertility and biomarkers

GLP‑1s can indirectly influence fertility through weight loss and improved metabolic health. Monitoring certain biomarkers before and during preconception planning helps guide decisions.

Important biomarkers to consider:

• Estradiol: Reflects ovarian function and helps assess follicular activity and menstrual cycle status.

• FSH (follicle‑stimulating hormone): Used to evaluate ovarian reserve and reproductive aging.

• HbA1c: Shows long‑term glycemic control; important because changes after stopping a GLP‑1 can affect pregnancy risks, especially in people with diabetes.

Clinical implications:

• Improved HbA1c and weight loss can restore ovulation in conditions like PCOS, but stopping therapy may reverse those benefits.

• If fertility treatment is planned, clinicians may time medication discontinuation to align with ovarian stimulation protocols and optimize ovulatory response.

Practical planning: dosing, washout, and alternatives

Discuss a tailored plan with your clinician; general considerations below can help guide that conversation.

Dosing and pharmacokinetics:

• Semaglutide (Wegovy for weight) is dosed weekly (commonly titrated to 2.4 mg weekly for weight management). Its half‑life is long (about one week), so systemic levels decline over several weeks after stopping.

• Liraglutide (Saxenda for weight) is a daily injection (up to 3.0 mg daily for weight); it has a shorter half‑life than semaglutide and clears more quickly.

• Oral semaglutide (Rybelsus) contains the same molecule as injectable semaglutide but differences in absorption and dosing frequency may influence timing decisions.

Washout timing and contraception:

• Exact washout periods are not standardized; clinicians often recommend stopping GLP‑1s before attempting conception and allow time for drug elimination based on agent half‑life.

• For weekly agents with longer half‑lives (e.g., semaglutide), clinicians may suggest a longer washout window (often several weeks) to ensure minimal systemic exposure.

• Maintain reliable contraception until you and your clinician agree it is safe to try to conceive.

Alternatives and bridging strategies:

• Lifestyle interventions (nutrition, physical activity) remain foundational and should be intensified if stopping pharmacotherapy.

• Metformin is commonly used in preconception care for people with PCOS and may be considered as a bridge for some patients; it has a more established safety profile in pregnancy.

• For people with diabetes, insulin adjustments or other diabetes agents with pregnancy safety data may be needed to maintain glucose targets.

• Discuss fertility‑preserving options and timing for assisted reproductive technologies if needed.

Comparing GLP‑1 forms when planning pregnancy

Different GLP‑1 formulations vary in dosing frequency, half‑life, and typical weight‑loss effect. These differences affect preconception planning.

Considerations by formulation:

• Long‑acting weekly injectables (semaglutide, tirzepatide GIP/GLP‑1‑related agent): longer washout periods; larger and sustained metabolic effects.

• Daily injectables (liraglutide): shorter half‑life and potentially faster clearance after stopping.

• Oral semaglutide: still contains semaglutide; pharmacologic exposure and elimination timelines are comparable to the injectable molecule, so similar caution is used.

Always verify agent‑specific recommendations with your clinician; product labels and local guidelines inform the safest approach.

Risks, contraindications, and who should avoid GLP‑1s when planning pregnancy

Who should not use GLP‑1s during preconception or pregnancy:

• Anyone who is pregnant or actively trying to conceive without clinician approval.

• People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2), per product warnings for some agents.

• Individuals with known contraindications to a specific GLP‑1 agent.

What to do if pregnancy occurs:

• Stop the GLP‑1 immediately and contact your clinician.

• Discuss alternative therapies and monitoring for glycemic control and maternal health.

• Evaluate the need for increased monitoring of fetal development per obstetric recommendations.

Clinical steps to plan safely

A practical preconception checklist to discuss with your clinician:

• Review current medications and confirm that GLP‑1 use will be paused before conception.

• Agree on an individualized washout interval based on the specific agent and reproductive plan.

• Monitor HbA1c and adjust diabetes therapy if needed to achieve pregnancy glycemic targets.

• Check reproductive biomarkers (estradiol, FSH) if fertility assessment is indicated.

• Reinforce diet, physical activity, and weight‑stability strategies; consider safe medication alternatives if metabolic control worsens.

• Coordinate contraception cessation with the washout and your fertility timeline.

Takeaways and conclusion

GLP‑1 receptor agonists can improve weight and glycemic control, which may enhance fertility for some people, but they are not recommended during pregnancy. Effective Wegovy pregnancy planning and broader GLP‑1 and fertility planning involve stopping the agent with an appropriate washout, maintaining metabolic health with safe alternatives, and monitoring biomarkers such as estradiol, FSH, and HbA1c. Work closely with your clinician to determine agent‑specific timing, replacement therapies, and monitoring to support a safer transition to pregnancy.

Join Mito to test 100+ biomarkers and get concierge-level guidance from your care team